Invega (Paliperidone) for the Treatment of Mania in Children and Adolescents Ages 6-17 With Bipolar Disorder

NCT00592358 | Terminated Phase 4 Results

• 1 other identifier: 2007-P-001525
• Study Type: interventional
• Target: 17
• Locations: 1 country
• Sites: 1

Brief Summary

This will be an 8-week open-label trial, using daily doses of paliperidone (Invega) in the treatment of children and adolescents who meet DSM-IV criteria of Bipolar I, Bipolar II, or Bipolar Spectrum Disorder. Specific hypotheses are as follows: Hypothesis 1: Bipolar Disorder symptomatology in children and adolescents with DSM-IV Bipolar I, Bipolar II, or Bipolar Spectrum Disorder will be responsive to Invega treatment. Hypothesis 2: Invega -associated improvement in bipolar disorder symptomatology in children and adolescents will translate into improved functional capacities (neuropsychological, social, and occupational), as well as an increased quality of life throughout treatment. Hypothesis 2: Invega treatment will be safe and well tolerated as reflected by a low drop out rate and absence of major side effects.

Conditions

Pediatric Bipolar Disorder

Keywords

bipolar disorder; children; adolescents; Invega

Outcome Measures

Primary Outcomes (1)

• Change in Symptoms Measured by Young Mania Rating Scale (YMRS)

  The YMRS is an 11-item instrument used to assess the severity of mania in patients with a diagnosis of bipolar disorder. Four items are graded on a 0 to 8 scale (irritability, speech, thought content, and disruptive/aggressive behavior), while the remaining seven itemsare graded on a 0 to 4 scale. The maximum possible total score is 60 (worse outcome, severe symptoms), and the minimum possible total score is 0 (no symptoms).

  Baseline and 8 weeks (or final study visit, if subjects completed the study before 8 weeks)

Secondary Outcomes (1)

• Change in Symptoms Measured by DSM-IV Mania Symptoms Checklist

  Baseline and 8 weeks (or final study visit, if subjects completed the study before 8 weeks)

Study Arms (1)

1

EXPERIMENTAL

Drug: paliperidone

Interventions

paliperidone DRUG

tablet, 3mgQAM - 6mgQAM, taken daily for 8 weeks

Also known as: Invega

1

Eligibility Criteria

• Age: 6 Years - 17 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17)

You may qualify if:

• Male and female outpatients 6-17 years of age (inclusive).
• Subjects with the diagnosis of Bipolar or Bipolar Spectrum Disorder and currently displaying manic, hypomanic, or mixed symptoms (with or without psychotic features), by DSM-IV, as manifested in clinical evaluation and confirmed by structured interview. Bipolar Spectrum Disorder (or sub- threshold bipolar disorder) is operationalized as having severe mood disturbance, which meets DSM-IV Criteria A for bipolar disorder but display fewer elements in Criteria B (only require 2 items for elation category and 3 for irritability).
• Subjects must score ≥ 20 on the YMRS.
• Subjects and their legal representative must have a level of understanding sufficient to communicate intelligently with the investigator and study coordinator, and to cooperate with all tests and examinations required by the protocol.
• Subjects and their legal representative must be considered reliable reporters.
• Each subject and his/her authorized legal representative must understand the nature of the study. The subject's authorized legal representative must sign an informed consent document and the subject must sign an informed assent document (if ≥ 7 years old).
• Subject must be able to participate in mandatory blood draws.
• Subject must be able to swallow pills.
• For concomitant therapy used to treat ADHD, subjects must have been on a stable dose of the medication for 1 month prior to study enrollment. The dose of the ADHD therapy will not change throughout the duration of the study.

You may not qualify if:

• Investigator and his/her immediate family; defined as the investigator's spouse, parent, child, grandparent, or grandchild.
• Serious, unstable illness including hepatic, renal, gastroenterological, respiratory, cardiovascular (including ischemic heart disease), endocrinologic, neurologic, immunologic, or hematologic disease.
• Uncorrected hypothyroidism or hyperthyroidism.
• Non-febrile seizures without a clear and resolved etiology.
• DSM-IV substance (except nicotine or caffeine) dependence within past 6 months.
• Judged clinically to be at serious suicidal risk.
• Any other concomitant medication with primary central nervous system activity other than specified in the Concomitant Medication portion of the protocol.
• Current diagnosis of schizophrenia.
• Mental retardation (IQ \< 75).
• Pregnant or nursing females.
• Known hypersensitivity to Invega® or similar formulations (paliperidone, risperidone).
• A non-responder or history of intolerance to Invega®, after treatment at adequate doses as determined by the clinician.
• Severe allergies or multiple adverse drug reactions.
• Subjects with a hematological disorder.
• Subjects with diabetes.

Sponsors & Collaborators

• Massachusetts General Hospital: lead

Study Sites (1)

Massachusetts General Hospital

Cambridge, Massachusetts, 02138, United States

Location

MeSH Terms

Conditions

Bipolar Disorder

Interventions

Paliperidone Palmitate

Condition Hierarchy (Ancestors)

Bipolar and Related Disorders; Mood Disorders; Mental Disorders

Intervention Hierarchy (Ancestors)

Isoxazoles; Azoles; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Pyrimidines

Results Point of Contact

• Title: Janet Wozniak, MD
• Organization: Massachusetts General Hospital

jwozniak@partners.org

(617)503-1038

Study Officials

• Janet Wozniak, MD

  Massachusetts General Hospital

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: Yes

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Associate Professor of Psychiatry at Harvard Medical School and at Massachusetts General Hospital

Study Record Dates

• First Submitted: December 28, 2007
• First Posted: January 14, 2008
• Study Start: November 1, 2007
• Primary Completion: December 1, 2009
• Study Completion: December 1, 2009
• Last Updated: July 4, 2012
• Results First Posted: July 4, 2012

Record last verified: 2012-06

Locations

US (1)